Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of **morphine** and **Exparel** (bupivacaine liposome injectable suspension). Morphine is an opioid analgesic that provides pain relief by acting primarily as an agonist at the mu-opioid receptor, leading to inhibition of pain pathways in the central nervous system. Exparel is a long-acting, non-opioid local anesthetic that delivers bupivacaine via a multivesicular liposome (DepoFoam) system for extended release, providing prolonged local or regional analgesia after surgery. The combination is not a standard fixed-dose product; both drugs may be used together in clinical pain management, though no specific, co-formulated product "morphine + Exparel" is approved.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morphine + Exparel.